Sosei Group (Sosei) has entered into a definitive distribution agreement with ASKA Pharmaceuticals (ASKA) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo).
NorLevo is an oral emergency contraceptive, morning after pill, which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo contains only levonorgestrel as an active ingredient. Sosei claimed that the dosing starts within 72 hours after unprotected sexual intercourse.
Sosei has acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA application for SOH-075 was submitted in Japan in September 2009.
The agreement is based on the terms of a binding letter of agreement that was announced on 22 October 2008. According to this agreement, Sosei will be responsible for development and registration and ASKA for sales and marketing.
Sosei is expected to receive upfront, milestone payments as well as a margin on product sales to ASKA.